[96a5a0]: / output / allTrials / identified / NCT00003731_identified.json

Download this file

438 lines (438 with data), 20.5 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
{
"info": {
"nct_id": "NCT00003731",
"official_title": "First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial",
"inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma with at least 25% oligodendroglial elements Recurrent or progressive disease following radiotherapy At least 3 months since prior radiotherapy Measurable disease by MRI or CT scan Lesion must have a diameter of at least 1 cm No progressive neurological deficits from the present recurrence No new neurological deficits interfering with daily activities No tumor causing midline shift or brain stem compression due to which a rapid deterioration is to be expected in case of no response No signs of increased intracranial pressure No extracranial disease\n\nPATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) AST/ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Renal: Creatinine clearance at least 60 mL/min Creatinine no greater than 1.25 times ULN Neurologic: See Disease Characteristics Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignant or nonmalignant diseases interfering with follow-up No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up\n\nPRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified Other: No other concurrent investigational drugs No other concurrent antitumor agents"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 70 Years",
"criterions": [
{
"exact_snippets": "maximum age of 70 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 70,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "DISEASE CHARACTERISTICS: Histologically proven oligodendroglioma or oligoastrocytoma with at least 25% oligodendroglial elements Recurrent or progressive disease following radiotherapy At least 3 months since prior radiotherapy Measurable disease by MRI or CT scan Lesion must have a diameter of at least 1 cm No progressive neurological deficits from the present recurrence No new neurological deficits interfering with daily activities No tumor causing midline shift or brain stem compression due to which a rapid deterioration is to be expected in case of no response No signs of increased intracranial pressure No extracranial disease",
"criterions": [
{
"exact_snippets": "Histologically proven oligodendroglioma or oligoastrocytoma",
"criterion": "histological diagnosis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"oligodendroglioma",
"oligoastrocytoma"
]
}
]
},
{
"exact_snippets": "at least 25% oligodendroglial elements",
"criterion": "oligodendroglial elements",
"requirements": [
{
"requirement_type": "percentage",
"expected_value": {
"operator": ">=",
"value": 25,
"unit": "%"
}
}
]
},
{
"exact_snippets": "Recurrent or progressive disease following radiotherapy",
"criterion": "disease status",
"requirements": [
{
"requirement_type": "status",
"expected_value": [
"recurrent",
"progressive"
]
}
]
},
{
"exact_snippets": "At least 3 months since prior radiotherapy",
"criterion": "time since prior radiotherapy",
"requirements": [
{
"requirement_type": "time elapsed",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Measurable disease by MRI or CT scan",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "assessment method",
"expected_value": [
"MRI",
"CT scan"
]
}
]
},
{
"exact_snippets": "Lesion must have a diameter of at least 1 cm",
"criterion": "lesion size",
"requirements": [
{
"requirement_type": "diameter",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "cm"
}
}
]
},
{
"exact_snippets": "No progressive neurological deficits from the present recurrence",
"criterion": "progressive neurological deficits",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No new neurological deficits interfering with daily activities",
"criterion": "new neurological deficits",
"requirements": [
{
"requirement_type": "interference with daily activities",
"expected_value": false
}
]
},
{
"exact_snippets": "No tumor causing midline shift or brain stem compression",
"criterion": "tumor effects",
"requirements": [
{
"requirement_type": "effects",
"expected_value": [
"no midline shift",
"no brain stem compression"
]
}
]
},
{
"exact_snippets": "No signs of increased intracranial pressure",
"criterion": "increased intracranial pressure",
"requirements": [
{
"requirement_type": "signs",
"expected_value": false
}
]
},
{
"exact_snippets": "No extracranial disease",
"criterion": "extracranial disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "PATIENT CHARACTERISTICS: Age: 18 to 70 Performance status: WHO 0-2 Life expectancy: At least 3 months Hematopoietic: Neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.25 times upper limit of normal (ULN) AST/ALT no greater than 2 times ULN Alkaline phosphatase no greater than 2 times ULN Renal: Creatinine clearance at least 60 mL/min Creatinine no greater than 1.25 times ULN Neurologic: See Disease Characteristics Other: Not pregnant or nursing Fertile patients must use effective contraception No other malignant or nonmalignant diseases interfering with follow-up No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up",
"criterions": [
{
"exact_snippets": "Age: 18 to 70",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 70,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "Performance status: WHO 0-2",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "WHO"
}
}
]
},
{
"exact_snippets": "Life expectancy: At least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
},
{
"exact_snippets": "Neutrophil count at least 1,500/mm3",
"criterion": "neutrophil count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 1500,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Platelet count at least 100,000/mm3",
"criterion": "platelet count",
"requirements": [
{
"requirement_type": "count",
"expected_value": {
"operator": ">=",
"value": 100000,
"unit": "mm3"
}
}
]
},
{
"exact_snippets": "Bilirubin no greater than 1.25 times upper limit of normal (ULN)",
"criterion": "bilirubin level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.25,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "AST/ALT no greater than 2 times ULN",
"criterion": "AST/ALT level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Alkaline phosphatase no greater than 2 times ULN",
"criterion": "alkaline phosphatase level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Creatinine clearance at least 60 mL/min",
"criterion": "creatinine clearance",
"requirements": [
{
"requirement_type": "clearance",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "mL/min"
}
}
]
},
{
"exact_snippets": "Creatinine no greater than 1.25 times ULN",
"criterion": "creatinine level",
"requirements": [
{
"requirement_type": "level",
"expected_value": {
"operator": "<=",
"value": 1.25,
"unit": "times ULN"
}
}
]
},
{
"exact_snippets": "Not pregnant or nursing",
"criterion": "pregnancy/nursing status",
"requirements": [
{
"requirement_type": "status",
"expected_value": false
}
]
},
{
"exact_snippets": "Fertile patients must use effective contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "use",
"expected_value": true
}
]
},
{
"exact_snippets": "No other malignant or nonmalignant diseases interfering with follow-up",
"criterion": "interfering diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study and follow-up",
"criterion": "conditions hampering compliance",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics Surgery: Not specified Other: No other concurrent investigational drugs No other concurrent antitumor agents",
"criterions": [
{
"exact_snippets": "No prior chemotherapy",
"criterion": "prior chemotherapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other concurrent investigational drugs",
"criterion": "concurrent investigational drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "No other concurrent antitumor agents",
"criterion": "concurrent antitumor agents",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}